TruScreen Update – Europe and Other Markets

NZX and Media Release 06 March, 2017

TruScreen Update – Europe and Other Markets
TruScreen enters into distribution agreements for Europe, Central Asia and Middle East
Cervical cancer technology company, TruScreen Limited (NZAX: TRU), the manufacturer of real time
cervical cancer screening technology, advises that it has entered into distribution agreements for the
sale of its TruScreen device in multiple new markets.

These agreements cover territories with a total screening population of 61 million women, and are
regions with a historical lack of quality cervical screening programs or with local screening practices
that vary considerably in quality.
Europe:
TruScreen has recently entered into agreements for distribution of its product into ten (10)
European countries including Serbia, Croatia, Macedonia, Montenegro, Kosovo, Bosnia and Slovenia,
Germany, Austria and Switzerland. These agreements cover a target screening population of
approximately 34 million women, ranging from countries with very poor access to health resources
to those with very well developed health resources.
Central Asia:
Following a recent visit to TruScreen by a delegation from Kazakhstan, which included
representatives of the Ministry of Health and Social Development of the Kazakhstan Government,
TruScreen has entered into an agreement for the distribution of the TruScreen device in the region.
Kazakhstan has approximately 5 million women of screening age.
Middle East:
TruScreen has also recently entered into an agreement for the distribution of TruScreen in Iran. Iran
has the largest population in the Middle East, with approximately 22 million women of screening
age.
CEO of TruScreen, Marty Dillon, said: “The launch of our second generation device, Truscreen2, has
further strengthened our proposition and we are now actively focused on building awareness and
sales of our technology into new territories. The execution of these distribution agreements
announced today, significantly enhances the potential for sales growth in Europe and other markets.
“It is evident from all our discussions that there is a great need and desire for an objective screening
technology such as TruScreen, which can operate in developing countries outside the traditional
laboratory infrastructure.”
TruScreen’s partners in these territories include Kebomed Europe AG, who have eight offices across
Northern and Western Europe.

-ENDS-
For more information visit www.truscreen.com or contact Martin Dillon, TruScreen Chief Executive Officer,
eMail: martindillon@truscreen.com
About TruScreen:
TruScreen’s real time cervical cancer
technology utilises a digital wand which is
placed on the surface of the cervix to measure
electrical and optical signals from the
surrounding tissue. A sophisticated proprietary
algorithm framework distinguishes between
normal and abnormal (cancerous and
precancerous) tissue to identify precancerous
change, or cervical intraepithelial neoplasia
(CIN). A Single Use Sensor (SUS) is used for
each patient to protect against cross-infection.